Takahashi H, Takizawa S, Hanano M, Tatewaki W, Nagasaki Y, Sasagawa Y, Shibata A
First Department of Internal Medicine, Niigata University School of Medicine.
Tohoku J Exp Med. 1987 Dec;153(4):295-302. doi: 10.1620/tjem.153.295.
Plasma levels of alpha 2-plasmin inhibitor (alpha 2PI), plasmin-alpha 2PI complex and cross-linked fibrin derivatives (XDP) were measured in 8 patients (12 episodes) with thromboembolic disorders on the initial administration of urokinase. In conjunction with a decrease in plasma alpha 2PI activity and antigen, plasmin-alpha 2PI complex increased following urokinase infusion in all cases except one who received a low dose (60,000 units) of urokinase. However, changes in XDP were variable among the patients. Plasma XDP level increased markedly in one, moderately in 4, slightly in one, and remained unchanged in 6 cases (episodes). The increment of plasma XDP correlated (r = 0.804, p = 0.003) with the dose of urokinase administered, but was independent of changes in plasmin-alpha 2PI complex. The plasma XDP elevation was associated with clinical improvement. These results suggest that simultaneous measurements of XDP and plasmin-alpha 2PI complex in plasma would be valuable for the pharmacological or hemostatic assessment of thrombolytic therapy.
对8例（12次发作）血栓栓塞性疾病患者在初次使用尿激酶时测定了血浆α2 - 纤溶酶抑制剂（α2PI）、纤溶酶 - α2PI复合物和交联纤维蛋白衍生物（XDP）的水平。除1例接受低剂量（60,000单位）尿激酶治疗的患者外，在所有病例中，随着尿激酶输注，血浆α2PI活性和抗原降低，纤溶酶 - α2PI复合物增加。然而，患者之间XDP的变化各不相同。血浆XDP水平在1例中显著升高，4例中度升高，1例轻度升高，6例（次发作）保持不变。血浆XDP的升高与尿激酶给药剂量相关（r = 0.804，p = 0.003），但与纤溶酶 - α2PI复合物的变化无关。血浆XDP升高与临床改善相关。这些结果表明，同时测定血浆中的XDP和纤溶酶 - α2PI复合物对于溶栓治疗的药理学或止血评估具有重要价值。
